ADC Therapeutics (ADCT) Capital Expenditures (2020 - 2026)

ADC Therapeutics (ADCT) has reported Capital Expenditures for 7 consecutive years, with $32000.0 the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures fell 87.88% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 94.67% YoY) and the FY2025 annual result came in at $264000.0, down 69.55% from the prior year.
• Capital Expenditures slipped to $32000.0 in Q1 2026 per ADCT's latest filing, from $264000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for ADCT reached as high as $1.2 million in Q2 2023 and fell as low as $30000.0 in Q2 2024.
• A 5-year average of $361857.1 and a median of $222500.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures soared 2324.0% — and 2024, when it slumped 97.52%.
• Year by year, Capital Expenditures stood at $214000.0 in 2022, then surged by 52.8% to $327000.0 in 2023, then slumped by 72.48% to $90000.0 in 2024, then surged by 193.33% to $264000.0 in 2025, then slumped by 87.88% to $32000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $32000.0, $264000.0, and $90000.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.